Program of enhanced infection control and prevention (IPC) guided by active and passive surveillance for carbapenem- and colistin-resistant Gram-negative organisms
- Conditions
- Health Condition 1: A499- Bacterial infection, unspecified
- Registration Number
- CTRI/2022/11/047361
- Lead Sponsor
- S Centers for Disease Control and Prevention
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Component 1 (passive surveillance)
Passive surveillance will occur for cultures sent from designated wards. All GN isolates found to be CRO by local standard of care AST may be included.
Component 2 (active surveillance)
Patients will be considered for inclusion in active surveillance who are identified as part of a contact investigation for an index case of a critical CRO or possible nosocomial transmission event or are admitted to a ward designated for universal active surveillance.
Component 3 (case investigation):Patients who have an isolate that is a critical CRO (rare or novel resistance mechanism or resistance to treatment) or identified as being part of possible nosocomial transmission will be included. Inpatient contacts identified through case investigation will be included.
Component 4 (enhanced IPC)
Individual patients will not be included in enhanced IPC. Wards selected for enhanced IPC will include ICUs and wards where critical CRO detection or nosocomial transmission is occurring.
Exclusion Criteria
• Species not considered to be of concern for IPC activities
• Age < 12 years
• Patient declines to participate in study activities
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CRO, CP-CRO, and CR-CRO per 1,000 patient days. <br/ ><br>prevalence of CRO, CP-CRO, and CR-CRO colonization at admission. <br/ ><br>Changes in thefrequency of CRO, CP-CRO, and CR-CROTimepoint: six monthly
- Secondary Outcome Measures
Name Time Method Change in technical capacity in bacteriology laboratories to detect and characterize CRO, CP-CRO, and CR-CROTimepoint: Baseline and endline